Invacare (NYSE:IVC) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Invacare (NYSE:IVCGet Rating) in a research note issued to investors on Friday. The firm set a “hold” rating on the health services provider’s stock.

Separately, Oppenheimer reduced their target price on Invacare to $2.00 in a report on Tuesday, November 15th.

Invacare Stock Performance

Shares of Invacare stock opened at $0.39 on Friday. Invacare has a one year low of $0.33 and a one year high of $3.80. The firm has a market capitalization of $14.73 million, a price-to-earnings ratio of -0.18 and a beta of 0.49. The business has a 50-day simple moving average of $0.68 and a 200 day simple moving average of $0.97. The company has a debt-to-equity ratio of 4.82, a current ratio of 1.32 and a quick ratio of 0.78.

Insider Buying and Selling

In other news, major shareholder Steven H. Rosen sold 60,480 shares of the firm’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $0.50, for a total transaction of $30,240.00. Following the transaction, the insider now directly owns 3,886,078 shares of the company’s stock, valued at $1,943,039. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Steven H. Rosen sold 60,480 shares of the stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $0.50, for a total transaction of $30,240.00. Following the completion of the sale, the insider now directly owns 3,886,078 shares in the company, valued at $1,943,039. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Steven H. Rosen sold 102,820 shares of the stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $0.38, for a total transaction of $39,071.60. Following the sale, the insider now owns 3,665,233 shares of the company’s stock, valued at $1,392,788.54. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 183,300 shares of company stock worth $79,112. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Invacare

Several institutional investors and hedge funds have recently made changes to their positions in the company. Brandes Investment Partners LP grew its position in Invacare by 77.7% in the 1st quarter. Brandes Investment Partners LP now owns 33,890 shares of the health services provider’s stock worth $48,000 after purchasing an additional 14,820 shares during the period. UBS Group AG grew its position in Invacare by 200.6% in the 1st quarter. UBS Group AG now owns 37,537 shares of the health services provider’s stock worth $53,000 after purchasing an additional 25,048 shares during the period. Fairhaven Wealth Management LLC bought a new stake in Invacare in the 1st quarter worth approximately $54,000. Hsbc Holdings PLC bought a new stake in Invacare in the 1st quarter worth approximately $54,000. Finally, Virtu Financial LLC bought a new stake in Invacare in the 1st quarter worth approximately $62,000. Institutional investors own 69.50% of the company’s stock.

Invacare Company Profile

(Get Rating)

Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. The company offers mobility and seating products, such as power wheelchairs under the Invacare TDX brand; custom manual wheelchairs under the Invacare, Invacare Top End, and Küschall brand names; and seating and positioning products under the Invacare brand, as well as custom molded seat modules under the PinDot brand.

See Also

Receive News & Ratings for Invacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invacare and related companies with MarketBeat.com's FREE daily email newsletter.